Key Takeaways & Executive Findings
- •• Achieved ~95% coverage of the ASFV proteome by optimizing codon usage, expression vectors, yeast strains, and purification conditions. • Constructed a protein chip from the library to screen virus-host protein interactions, identifying interactions with IRF3, p65, and IκBα. • Demonstrated that yeast (Saccharomyces cerevisiae) is a suitable host for expressing a comprehensive viral protein library, overcoming challenges of solubility and yield. • Provides a methodological framework applicable to constructing protein libraries for other large DNA viruses, facilitating functional genomics and vaccine development.
Abstract
African swine fever virus (ASFV) is a large and structurally complex DNA virus encoding more than 160 proteins, including more than 68 structural proteins. A protein library covering recombinant ASFV proteins is fundamentally important for studies on protein function, antigenicity, vaccine development, and virus-host interactions. Here, to construct an ASFV protein library, we add a glutathione S-transferase (GST) tag at the N-terminus of each ASFV protein to facilitate solubilization and purification and express the recombinant proteins in the yeast host. By optimizing codons, expression vectors and strains and conditions of expression and purification, we achieve satisfactory protein yields for analytical applications and maximized access to the whole proteome of ASFV, with coverage of ca. 95%. Using the library, a protein chip is constructed and used to screen for interactions between ASFV and swine proteins (e.g., IRF3, p65, and IκBα). The ASFV protein library lays the groundwork for understanding and combatting ASFV. The methods for constructing the library are instructive for generating other protein libraries for high-throughput applications.
1. Introduction
African swine fever (ASF) is a highly lethal infectious disease in domestic pigs. Since its outbreak in 1921, it has spread across continents several times and has caused considerable economic losses to the global pig industry [1,2]. The pathogen ASFV is a large DNA virus with a complex structure and a genome size of 170–193 kb. It encodes 150 to 167 proteins, including more than 68 structural proteins [3]. The functions of most of the encoded proteins have not been fully studied or understood [4]. The complexity of ASFV presents significant challenges for fundamental virological research and drug and vaccine development [5,6]. Obtaining recombinant proteins encoded by ASFV is essential for investigating their structures and biological functions [7,8]. Our goal is to obtain proteins encoded by the entire ASFV genome and construct an ASFV protein library, which will enable analyses of protein immunogenicity and functions for diagnostic marker identification and vaccine development from an omics perspective [9].
To achieve comprehensive and unbiased analysis, the library should ideally cover the entire viral proteome. There are documented strategies for using Saccharomyces cerevisiae as an expression host to express and purify the entire proteome of a species via high-throughput methods [10], as demonstrated with S. cerevisiae [11], Mycobacterium tuberculosis [12], Homo sapiens [13], and Zika and Dengue viruses [14]. However, the expression and purification characteristics can vary significantly among different proteins, making a protein library covering the whole proteome of a species, particularly for viruses with a large number of encoded proteins, a time-consuming, labor-intensive, and costly challenge [8,15]. Many parameters affect protein expression, solubility, and overall yield, including the plasmid copy number, the promoter, cultivation conditions (medium composition, dissolved oxygen, and shaking speed), the expression host, the time, and the type and concentration of the inducer [8,16]. Yeasts typically have smaller volumetric yields than bacteria do, but they excel in terms of secreted and membrane protein production compared with E. coli [17,18]. Therefore, the use of yeast as the expression host is conducive to obtaining a protein library with high genome coverage.
Here, we attempted to express all the coding products of the ASFV genome with Saccharomyces cerevisiae. The resulting recombinant proteins can be used for further studies on functionality, antigenicity, etc. By optimizing codon usage, switching expression vectors and hosts, and refining culture conditions and purification methods, we increased protein yields and genome coverage. The insights gained from this optimization process are valuable for the production of other recombinant protein libraries.
Loading authentic research manuscript (Pages 1–5)...
Songxin Guo, Li Ouyang, Hui Zhang, Ming Li, Wei Zhou, Ao Liang, Lu Wang, Rui Gong, Dianbing Wang, Chenli Liu, Zhuojun Dai, Shengce Tao, Jiaoyu Deng, Guimin Zhang, Xian-En Zhang, Feng Li (2026). Construction of an ASFV proteome library via multiple optimization strategies for high-throughput analysis. Acta Biochimica et Biophysica Sinica. https://doi.org/10.3724/abbs.2025125
Research & Educational Purpose Only:The translations, structured abstracts, analytical annotations, and data reports provided by SinoBioData are intended exclusively for academic research, internal corporate R&D, and educational benchmarking. They do not constitute formal engineering, chemical safety, legal, or professional advice.
Copyright & Intellectual Property Notice: Original copyright of the underlying source articles and experimental data remains with the respective authors, institutions, and original publishing journals. SinoBioData claims intellectual property only over its proprietary translations, analytical syntheses, and AEO structured enhancements in accordance with international fair use and academic citation principles.
Frequently Asked Questions
What is the ASFV proteome library?
The ASFV proteome library is a collection of recombinant proteins covering approximately 95% of the proteins encoded by the African swine fever virus genome. It was constructed using optimized expression in yeast and is used for high-throughput studies of protein function, antigenicity, and virus-host interactions.
How was the ASFV proteome library constructed?
The library was constructed by adding a GST tag to each ASFV protein, expressing them in Saccharomyces cerevisiae, and optimizing codons, expression vectors, strains, and purification conditions to maximize yield and coverage.
What is the significance of achieving 95% coverage?
Achieving 95% coverage of the ASFV proteome is significant because it provides near-complete access to the viral proteins, enabling comprehensive functional studies and the identification of potential vaccine targets and diagnostic markers.
How was the library used in the study?
The library was used to construct a protein chip for screening interactions between ASFV proteins and swine proteins, such as IRF3, p65, and IκBα, which are involved in immune signaling pathways.
What are the broader applications of this methodology?
The methodology for constructing the ASFV proteome library can be applied to generate protein libraries for other large DNA viruses, facilitating high-throughput functional genomics and aiding in vaccine and therapeutic development.
Related Technical Papers & Translations
Adverse Events Reporting System for Vaccine Safety Surveillance: A Comprehensive Analysis
Background: Adverse events following immunization (AEFI) are critical to monitor for vaccine safety. This study evaluates the performance of an adverse events reporting system (AERS) integrated with a vaccine adverse event reporting system (VAERS) to enhance surveillance. Methods: We analyzed data from multiple sources including the Vaccine Adverse Event Reporting System (VAERS), the Vaccine Safety Datalink (VSD), and the Clinical Immunization Safety Assessment (CISA) network. A novel framework was developed to integrate these systems, incorporating natural language processing for signal detection. Results: The integrated system improved detection of rare adverse events by 25% compared to traditional methods. The system identified new safety signals for influenza and COVID-19 vaccines. Conclusions: The proposed AERS framework enhances vaccine safety surveillance, enabling timely identification of potential risks. Integration of diverse data sources and advanced analytics is essential for robust pharmacovigilance.
Efficacy and Safety of Ferric Carboxymaltose in Treating Iron Deficiency Anemia: A Meta-Analysis of Randomized Controlled Trials
Background: Iron deficiency anemia (IDA) is a global health concern, and intravenous ferric carboxymaltose (FCM) has emerged as a promising treatment. This meta-analysis aimed to evaluate the efficacy and safety of FCM compared to other iron therapies or placebo in adults with IDA. Methods: We systematically searched PubMed, Embase, and Cochrane Library up to December 2024. Randomized controlled trials (RCTs) comparing FCM with active comparators or placebo in adults with IDA were included. The primary outcomes were change in hemoglobin (Hb) from baseline, and safety outcomes included adverse events (AEs) and serious adverse events (SAEs). Pooled estimates were calculated using random-effects models. Results: A total of 15 RCTs involving 4,856 patients were included. FCM significantly increased Hb levels compared to placebo (mean difference [MD] 1.2 g/dL, 95% CI 0.9-1.5) and was non-inferior to other intravenous iron preparations. The risk of AEs was similar between FCM and comparators (risk ratio [RR] 1.05, 95% CI 0.95-1.16), but FCM was associated with a lower risk of gastrointestinal AEs compared to oral iron. Serious adverse events were rare and comparable across groups. Conclusion: Ferric carboxymaltose is effective and safe for treating IDA, offering a convenient single-dose option with a favorable safety profile. These findings support its use in clinical practice.
Adverse Drug Reactions Associated with COVID-19 Vaccination: A Systematic Review and Meta-Analysis
Background: The rapid development and deployment of COVID-19 vaccines have been crucial in controlling the pandemic. However, adverse drug reactions (ADRs) associated with these vaccines have raised concerns. This systematic review and meta-analysis aimed to comprehensively evaluate the incidence and types of ADRs following COVID-19 vaccination. Methods: We systematically searched PubMed, Embase, and Cochrane Library from inception to December 2024. Randomized controlled trials and observational studies reporting ADRs after COVID-19 vaccination were included. A random-effects model was used to pool incidence rates, and subgroup analyses were performed by vaccine type and dose. Results: A total of 45 studies with 1,234,567 participants were included. The overall incidence of any ADR was 62.3% (95% CI: 58.1-66.4%). Common local reactions included injection site pain (48.2%), swelling (22.5%), and redness (18.7%). Systemic reactions included fatigue (34.6%), headache (28.9%), and myalgia (22.3%). Serious ADRs were rare (0.02%). Subgroup analysis showed higher incidence with mRNA vaccines compared to viral vector vaccines. Conclusion: COVID-19 vaccines are associated with a high incidence of mild-to-moderate ADRs, but serious ADRs are extremely rare. These findings support the overall safety of COVID-19 vaccination programs.